" class="no-js "lang="en-US"> ABL and Coave Therapeutics Collaborate to Develop Manufacturing Processes and Create Joint Capabilities for Process Development - Medtech Alert
Friday, December 06, 2024

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
ABL and Coave Therapeutics Collaborate to Develop Manufacturing Processes and Create Joint Capabilities for Process Development | Pharmtech Focus

June 10 2022

ABL and Coave Therapeutics Collaborate to Develop Manufacturing Processes and Create Joint Capabilities for Process Development

Coave Therapeutics (‘Coave’), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases, and ABL, a pure play Contract Development and Manufacturing Organization (CDMO) specialized in the development and manufacturing of viruses for vaccine candidates, gene and cancer therapies, today announce that they have entered into a strategic collaboration to develop gene therapy manufacturing processes. The financial terms are not disclosed.
Under the two-stage collaboration both companies will initially combine their complementary expertise to co-develop manufacturing technologies for AAV-based gene therapy products. ABL and Coave’s process development teams will work jointly in ABL’s state-of-the-art GMP facility in Lyon, France.
The second stage of the collaboration provides Coave with an exclusive option to secure process development capacity and laboratory space within ABL’s facility. This will enable Coave to further develop and scale-up manufacturing technologies for AAV-based products, including its proprietary next-generation AAV-Ligand Conjugate vectors (ALIGATER) platform. The deal will also strengthen Coave’s ability to generate large-scale and high-quality gene therapy products based on this new generation of advanced AAV vectors.

“Our collaboration with ABL, a best-in-class and complementary partner for Coave, is a major step in our strategy towards the vertical integration of our R&D capacities, which will be crucial in enabling us to control the development and manufacture of our pipeline products in an end-to-end manner. The manufacturing processes developed through this partnership will be critical on the path to achieving our future clinical and commercial development milestones, in particular for our CNS programs addressing large patient populations,” said Rodolphe Clerval, CEO, Coave Therapeutics.

Patrick Mahieux, general manager, ABL Europe, said: “We are delighted to join forces with Coave, a fellow French company. This exclusive partnership aims to bring together our knowledge and expertise to co-develop a state-of-the-art manufacturing process for viral vectors used in cell and gene therapies. We are excited to welcome Coave’s team of expert scientists to our facilities in Lyon to jointly accelerate the development of an AAV manufacturing platform. We look forward to a long-term partnership enabling the development and manufacturing of innovative cell and gene therapy treatments in France.”

People In This Post

Rodolphe Clerval

Rodolphe Clerval

Companies In This Post

Coave Therapeutics | Pharmtech Focus

Coave Therapeutics
  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients

    Clinical Trials

     Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS

    Clinical Trials

     Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board

    Appointments

     Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera

    News

     Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic

    Clinical Trials

     Read more
More On